Research and Development
THX-150: A Pharmaceutical Formulation of Cannabinoids with a Selected Antibacterial Agent for Infectious Diseases Caused by Multidrug Resistant (MDR) Bacteria
According to the World Health Organization, antimicrobial resistance, classified as a ‘serious threat’, occurs when microorganisms are exposed to antimicrobial drugs. As a result, medicines become ineffective and infections persist, increasing the risk of spread. Antimicrobial resistance increases the cost of healthcare with lengthier stays in hospitals and more intensive care required.
According to the U.S. Centers for Disease Control and Prevention, antibiotic-resistant infections add considerable costs to the U.S. healthcare system. In most cases, antibiotic-resistant infections require prolonged and/or costlier treatments, extend hospital stays, necessitate additional doctor visits and healthcare use, and result in greater disability and death compared with infections that are easily treatable with antibiotics.
THX-150 is a drug candidate intended for the treatment of infectious diseases. It is a pharmaceutical formulation of cannabinoids with a selected antibacterial agent and possesses antimicrobial synergy potential. Antibiotics are a type of antimicrobial drug used in the treatment and prevention of bacterial infection.